PFIZER INC — Capital/Financing Update 2016

Nov 14, 2016

8-K 1 a16-21499_38k.htm 8-K

*UNITED STATES*

*SECURITIES AND EXCHANGE COMMISSION*

*Washington, D.C. 20549*

*FORM 8-K*

*CURRENT REPORT*

*PURSUANT TO SECTION 13 OR 15(d)*

*OF THE SECURITIES EXCHANGE ACT OF 1934*

Date of report (Date of earliest event reported): November 14, 2016

*PFIZER INC.*

(Exact name of registrant as specified in its charter)

Delaware	1-3619	13-5315170
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

235 East 42nd Street New York, New York	10017
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (212) 733-2323

*Not Applicable*

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SEQ.=1,FOLIO='',FILE='C:\JMS\108645\16-21499-3\task8170020\21499-3-ba.htm',USER='108645',CD='Nov 12 23:58 2016'

*Item 8.01 Other Events*

On November 14, 2016, Pfizer Inc. (the “Company”) issued a press release announcing the commencement of a tender offer (the “Tender Offer”) to purchase for cash any and all of its outstanding 6.200% Senior Notes due March 15, 2019.

The Tender Offer is being made exclusively pursuant to an offer to purchase dated November 14, 2016 and related letter of transmittal and notice of guaranteed delivery, which set forth the terms and conditions of the Tender Offer.

A copy of the Company’s press release announcing the Tender Offer is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

*Item 9.01 Financial Statements and Exhibits*

(d) Exhibits

Exhibit No.	Exhibit Description
99.1	Press Release of Pfizer Inc., dated November 14, 2016.

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\108645\16-21499-3\task8170020\21499-3-ba.htm',USER='108645',CD='Nov 12 23:58 2016'

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

By:	/s/ Margaret M. Madden
	Margaret M. Madden
	Vice President and Corporate Secretary
	Chief Governance Counsel
Dated: November 14, 2016

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\108645\16-21499-3\task8170020\21499-3-ba.htm',USER='108645',CD='Nov 12 23:58 2016'

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release of Pfizer Inc., dated November 14, 2016.

4

SEQ.=1,FOLIO='4',FILE='C:\JMS\108645\16-21499-3\task8170020\21499-3-ba.htm',USER='108645',CD='Nov 12 23:58 2016'